A Phase 3 interventional study of efgartigimod and Placebo in Primary Immune Thrombocytopenia, sponsored by argenx. Completed at 121 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-13.
Sponsored by argenx · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Turkey — 6 open to participants now, 10 under way, 7 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Turkey.
Among the 19 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Turkey, this one is the 11th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2019, is one of 13 in phase 3, and was the 4th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →6 of the 19 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Turkey are open now. Recruiting first, the newest first:
Grand Shuyang Life Sciences (Chengdu) Co., Ltd. · Sites in Turkey
Ages 18–65
Takeda · Sites in Turkey, United States, Australia and 12 more countries
Ages 18+
Kedrion S.p.A. · Sites in Turkey, United States, Czechia and 5 more countries
Ages 18–70
Takeda · Sites in Turkey, United States, Australia and 15 more countries
Ages 18+
Chugai Pharmaceutical · Sites in Turkey, United States, Australia and 17 more countries
Ages 18–85
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 13
First in 2011; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 131 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 144 across the 18 interventional studies, 500 across the 1 observational. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 19 have an industry lead sponsor. The 10 most frequent:
argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.
argenx has 8 studies filed under Purpura, Thrombocytopenic, Idiopathic — fewer than ten, so there is no comparison to draw.
4 of the studies in Purpura, Thrombocytopenic, Idiopathic with a site in Turkey that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059000Phase 3Kedrion S.p.A.A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) | 2026-12 |
| NCT07233213Phase 3Grand Shuyang Life Sciences (Chengdu) Co., Ltd.An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia | 2026-12 |
| NCT04812925Phase 3argenxA Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | 2027-10 |
| NCT06371417Chugai PharmaceuticalPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 2027-03-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 19 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in participants with primary ITP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient receiving efgartigimod
Biological: efgartigimod
Patients receiving placebo
Other: Placebo
Intravenous infusion of efgartigimod
Also known as: ARGX-113
Intravenous infusion of placebo
Percentage of Participants With Chronic ITP With a Sustained Platelet Count Response Defined as Achieving Platelet Counts of at Least 50×10^9/L for at Least 4 of the 6 Visits Between Week 19 and 24 of the Trial.
Percentage of participants with chronic ITP with a sustained platelet count response was defined as achieving platelet counts of at least 50 × 10\^9/L for at least 4 of the 6 visits between Week 19 and 24 of the study.
Time frame: From Week 19 up to Week 24
Extent of Disease Control Defined as the Number of Cumulative Weeks Over the Planned 24-week Treatment Period With Platelet Counts of ≥50×10^9/L in the Chronic ITP Population
Extent of disease control, defined as the cumulative number of weeks over the planned 24-week treatment period with platelet counts of ≥50 × 10\^9/L in the chronic ITP population.
Time frame: From Week 1 up to Week 24
Percentage of Participants With a Sustained Platelet Count Response for at Least 4 of the 6 Visits Between Week 19 and 24 of the Study
Percentage of participants in the overall population (chronic and persistent ITP) with a sustained platelet count response, defined as achieving platelet counts of at least 50 × 10\^9/L for at least 4 of the 6 visits between weeks 19 and 24 of the study.
Time frame: From Week 19 up to Week 24
Incidence and Severity of the WHO-classified Bleeding Events
Incidence of the World Health Organization (WHO)-classified bleeding events in the overall population. This secondary endpoint used the WHO-classified bleeding scale. Bleeding was the predominant clinical manifestation of ITP and was typically related to platelet count. Accordingly, measuring bleeding was important for monitoring this participant population.
Time frame: From Week 1 to Week 24
Percentage of Participants in the Overall Population Achieving Platelet Counts of at Least 50×10^9/L for at Least 6 of the 8 Visits Between Week 17 and Week 24
Percentage of participants in the overall population achieving platelet counts of at least 50 × 10\^9/L for at least 6 of the 8 visits between Week 17 and 24 of the study.
Time frame: From Week 17 up to Week 24
This study was conducted at 71 active sites that enrolled participants in 18 countries. Recruitment started on 09 December 2019.
| Milestone | Efgartigimod | Placebo |
|---|---|---|
| Started | 86 | 45 |
| Completed | 64 | 32 |
| Not completed | 22 | 13 |
| Withdrew: Withdrawal by subject | 10 | 3 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Lack of efficacy | 8 | 5 |
| Withdrew: Other | 0 | 3 |
Percentage of participants with chronic ITP with a sustained platelet count response was defined as achieving platelet counts of at least 50 × 10\^9/L for at least 4 of the 6 visits between Week 19 and 24 of the study.
| Percentage of participants | Efgartigimod | Placebo |
|---|---|---|
| Percentage of Participants With Chronic ITP With a Sustained Platelet Count Response Defined as Achieving Platelet Counts of at Least 50×10^9/L for at Least 4 of the 6 Visits Between Week 19 and 24 of the Trial. | 21.8 | 5.0 |
Extent of disease control, defined as the cumulative number of weeks over the planned 24-week treatment period with platelet counts of ≥50 × 10\^9/L in the chronic ITP population.
| Weeks | Efgartigimod | Placebo |
|---|---|---|
| Extent of Disease Control Defined as the Number of Cumulative Weeks Over the Planned 24-week Treatment Period With Platelet Counts of ≥50×10^9/L in the Chronic ITP Population | 2.00 (0.00 to 11.00) | 0.00 (0.00 to 1.00) |
Percentage of participants in the overall population (chronic and persistent ITP) with a sustained platelet count response, defined as achieving platelet counts of at least 50 × 10\^9/L for at least 4 of the 6 visits between weeks 19 and 24 of the study.
| Percentage of participants | Efgartigimod | Placebo |
|---|---|---|
| Percentage of Participants With a Sustained Platelet Count Response for at Least 4 of the 6 Visits Between Week 19 and 24 of the Study | 25.6 | 6.7 |
Incidence of the World Health Organization (WHO)-classified bleeding events in the overall population. This secondary endpoint used the WHO-classified bleeding scale. Bleeding was the predominant clinical manifestation of ITP and was typically related to platelet count. Accordingly, measuring bleeding was important for monitoring this participant population.
| bleeding events | Efgartigimod | Placebo |
|---|---|---|
| Incidence and Severity of the WHO-classified Bleeding Events | 4.0 (1.0 to 10.0) | 5.0 (2.0 to 14.0) |
Percentage of participants in the overall population achieving platelet counts of at least 50 × 10\^9/L for at least 6 of the 8 visits between Week 17 and 24 of the study.
| Percentage of participants | Efgartigimod | Placebo |
|---|---|---|
| Percentage of Participants in the Overall Population Achieving Platelet Counts of at Least 50×10^9/L for at Least 6 of the 8 Visits Between Week 17 and Week 24 | 22.1 | 6.7 |
Collected over Full study duration (31 Weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Efgartigimod | 0/86 (0%) | 7/86 (8.1%) | 80/86 (93%) |
| Placebo | 0/45 (0%) | 7/45 (15.6%) | 43/45 (95.6%) |
| Event | Efgartigimod | Placebo |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 2/86 | 0/45 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/86 | 1/45 |
| AnaemiaBlood and lymphatic system disorders | 0/86 | 1/45 |
| Immune thrombocytopeniaBlood and lymphatic system disorders | 0/86 | 1/45 |
| Mouth haemorrhageGastrointestinal disorders | 0/86 | 1/45 |
| Acute kidney injuryRenal and urinary disorders | 0/86 | 1/45 |
| HaematuriaRenal and urinary disorders | 0/86 | 1/45 |
| AppendicitisInfections and infestations | 0/86 | 1/45 |
| COVID-19Infections and infestations | 0/86 | 1/45 |
| Chronic myelomonocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/86 | 0/45 |
| Event | Efgartigimod | Placebo |
|---|---|---|
| Blood urine presentInvestigations | 31/86 | 17/45 |
| PetechiaeSkin and subcutaneous tissue disorders | 13/86 | 12/45 |
| HaematomaVascular disorders | 8/86 | 11/45 |
| ContusionInjury, poisoning and procedural complications | 17/86 | 6/45 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 8/86 | 8/45 |
| HeadacheNervous system disorders | 14/86 | 6/45 |
| HaematuriaRenal and urinary disorders | 14/86 | 6/45 |
| Mouth haemorrhageGastrointestinal disorders | 7/86 | 7/45 |
| Gingival bleedingGastrointestinal disorders | 4/86 | 6/45 |
| EcchymosisSkin and subcutaneous tissue disorders | 5/86 | 6/45 |
Full Analysis Set: All randomized participants.
| Age, Categorical(Participants) | Efgartigimod | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 75 | 32 | 107 |
| >=65 years | 11 | 13 | 24 |
| Age, Continuous(years) | Efgartigimod | Placebo | Total |
|---|---|---|---|
| Mean | 46.9 ± 16.55 | 51.7 ± 17.93 | 48.6 ± 17.12 |
| Sex: Female, Male(Participants) | Efgartigimod | Placebo | Total |
|---|---|---|---|
| Female | 47 | 24 | 71 |
| Male | 39 | 21 | 60 |
| Race (NIH/OMB)(Participants) | Efgartigimod | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 5 | 3 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 80 | 41 | 121 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Efgartigimod | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 1 | 5 |
| Not Hispanic or Latino | 77 | 40 | 117 |
| Japanese | 5 | 3 | 8 |
| Unknown or Not reported | 0 | 1 | 1 |
Showing the first 100 of 121 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2019 to primary completion in Feb 2022, 25 months.
Results were first posted in Mar 2025, 3 years 1 month after primary completion. A results delay was requested in Feb 2023.
Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 25 months is close to that.
Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efgartigimod alfa
Purpura, Thrombocytopenic, Idiopathic →